Using AI to sequence fungi genomes for cancer treatments, Hexagon Bio nets $47M in Series A
A Stanford spinout exploring how fungi can be sequenced to discover new medicines in oncology and infectious diseases now has significantly more cash to do so.
Early Tuesday morning, Hexagon Bio announced the closing of their Series A financing, pulling in $47 million from a group of investors led by The Column Group. The round, which also saw participation from 8VC and Two Sigma Ventures, will go toward creating a proprietary genomics database as well as building out a drug discovery team to develop the new compounds. Hexagon brought on Tod Smeal as its new CSO after he served in the same position at Lilly Research Labs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.